Invention Grant
- Patent Title: Endoinulinases
-
Application No.: US17163521Application Date: 2021-01-31
-
Publication No.: US11655463B2Publication Date: 2023-05-23
- Inventor: Itamar Yadid , Rami Cohen , Livnat Afriat-Jurnou
- Applicant: MIGAL GALILEE RESEARCH INSTITUTE LTD.
- Applicant Address: IL Kiryat Shmona
- Assignee: MIGAL GALILEE RESEARCH INSTITUTE LTD.
- Current Assignee: MIGAL GALILEE RESEARCH INSTITUTE LTD.
- Current Assignee Address: IL Kiryat Shmona
- Agency: The Roy Gross Law Firm, LLC
- Agent Roy Gross
- Main IPC: C12N9/24
- IPC: C12N9/24 ; C12N15/74

Abstract:
A modified endoinulinase is provided, comprising modified wild-type T. purpuregenus endoinulinase, or a functional fragment thereof, in which an amino acid residue at each one of one or more positions corresponding to 128, 316, 344, 350 or 504 of wild-type T. purpuregenus endoinulinase is substituted, wherein: (i) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; and a threonine residue corresponding to T504 is substituted with M, S or Y; and optionally an alanine residue corresponding to A316 is substituted with T, S, C or M; (ii) a tyrosine residue corresponding to Y128 is substituted with H, K or R; a glutamate residue corresponding to E344 is substituted with K, H or R; a threonine residue corresponding to T504 is substituted with M, S or Y; and a glutamine residue corresponding to Q350 is substituted with L, G, A, V or I; or (iii) a tyrosine residue corresponding to Y128 is substituted with H, K or R.
Public/Granted literature
- US20210155914A1 IMPROVED ENDOINULINASES Public/Granted day:2021-05-27
Information query